|
Peer Review Journals
Conference Abstracts
Oral / Platform Presentations
Poster Presentations
Peer Review Journal
Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
J Brettschneider, TD Jaskowski, H Tumani, S Abdul, D Husebye, H Seraj, HR Hill, E Fire, L Spector, J Yarden , N Dotan and JW Rose
J Neuroimmunol 2009; 217;95-101
Anti-alpha-glucose based glycan IgM antibodies predict relapse Activity in Multiple Sclerosis after the first neurological event.
MS Freedman, J Laks, N Dotan, RT Altstock, A Dukler, and CJM Sindic
Mult Scler 2009; 15: 422-430.
Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
M Schwarz , L Spector , M Gortler , O Weishaus , L Glass-Marmor , A Karni , N Dotan , A Miller
J Neurol Sci 2006;244:59-68.
Conference Abstracts
Oral / Platform Presentations
2010 AAN 62nd Annual Meeting:
Yarden J, Schmidt H, Frederiksen J, Tumani H, Brettschneider J, Abdul S, Jarius S, Wildemann B, Franciotta D, S Larissa , Fire E, Dotan N.
Antibodies (gMS[Dx Test) Differentiate Newly Diagnosed Relapsing Remitting Multiple Sclerosis Patients from Other Inflammatory Demyelinating Disease Patients within One Year from Diagnosis.
2006 AUTOIMMUNITY 5th International Congress:
Prognosis in Multiple Sclerosis.
C Sindic. Abstracts of 5th international Congress on Autoimmunity , Autoimmunity Reviews.
2006; ISSN 1568-9972:p 203.
2010 ACTRIMS 15th Annual Meeting
Yarden J, Schmidt H, Spector L, Fire E, Loud S, Dotan N, Venkatesan A, Frohman EM, Sadiq SA, Thrower BW, Riskind P, Racke MK, Vollmer TL and Kinkel RP.
ACTRIMS 2010; P41.
J Yarden, H Schmidt, J Frederiksen, H Tumani, J Brettschneider, S Abdul, S Jarius, B Wildemann, D Franciotta, L Spector, E Fire and N Dotan.
ACTRIMS2010; P42.
2009 ACTRIMS
H Tumani, J Brettschneider, TD Jaskowski, S Abdul, D Husebye, H Seraj, HR Hill, E Fire, J Yarden, L Spector, N Dotan, JW Rose
2009 ECTRIMS:
Anti-alpha-glucose based glycan IgM antibodies in patients with a clinically isolated syndrome:
analyses from the BEtageron® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study
M Freedman, G Edan, HP Hartung, L Kappos, D Miller, X Montalban, CH Polman, N Dotan, V Lanius,
C Metzig, S Schwenke, C Pohl, R Sandbrink for the BENEFIT Study Group
Mult Scler 2009; 15: S71.
2008 ACTRIMS/ECTRIMS/LACTRIMS Joint Meeting:
Performance of an anti-GAGA4 IgM assay in distinguishing multiple sclerosis patients from control groups in a US cohort: a cross sectional retrospective study
TD Jaskowski, D Husebye, HS Seraj, J Yarden, L Spector, E Fire, N Dotan, HR Hill, JW Rose
Mult Scler 2008; 14: S282.
|
|
|
|
